Please assess the completion status of the following clinical trial:

Trial Title: RSHF in Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> or = 18 years~* Social Insurance~* Performance Index \<2~* Life expectancy\> 6 months~* adenocarcinoma colorectal (histologically proven)~* Metastases (inoperable or recurrent after surgery),~* hepatic localization and / or lung (up to 3 if one organ metastasis or 3 in total if the two bodies are metastatic). The largest diameter of the metastasis will \< ou = 6cm for the liver, \< or = 6 cm for the lung. If multiple metastases, the sum of their maximum diameter is 6cm \< ou = the liver, \< ou = 6 cm for the lung.~* Lesion (s) measurable (s) and evaluable (s)~* CT less than 3 weeks~* Patients must have received at least one prior chemotherapy regimen containing 5FU~  • Patients may have received one or more lines of chemotherapy including irinotecan.~* bilirubin \<1.5 x ULN~* AST and ALT \<5x ULN~* neutrophils\> 1.5x109 / L, platelets\> 100x109 / L, hemoglobin\> 9 g / dL~* TP, TCA Normal (only for patients treated with a permanent implant)~* Informed consent signed.~Exclusion Criteria:~* contraindication to the administration of irinotecan.~* History of radiotherapy in the thoraco-abdominal-cons indicating further irradiation.~* History of other invasive cancer treated in a period of less than 5 years (basal cell carcinoma and non-invasive cervical excepted)~* Metastatic disease diffuse or more than three metastases in the liver and / or lung during the natural history of disease (excluding any patient is having a complete radiological response on several metastases although 1-3 residual after treatment ( s) medical (at)).~* Location (s) tumor (s) = CTV to less than 12 mm laterally or less than 15 mm in the cranio-caudal, stomach, small intestine, esophagus, trachea, bronchi of right and left pulmonary arteries and right and left.~* Pregnancy or breastfeeding.~  - Lack of means or refusal to use effective contraception for men or women of childbearing age.~* Any other concomitant experimental treatment.~* Any other concurrent anticancer therapy, immunotherapy or hormonal therapy.~* Monitoring impossible because of psychological, sociological or because of geographical distance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiation + Irinotecan (Type: OTHER): Irinotecan will be administered :~- 40 mg/m² in serum physiologique during 30 to 90 min at D1 and D8 of radiotherapy~Radiotherapy (RSHF) will be administered :~* at D1, D3, D8 and D10~* 48 Gy, 12 Gy by fractions twice a week

Based on this trial design, predict the completion outcome and termination type (if applicable).